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Abstract: Introduction: This paper aims to determine the effectiveness and sensitivity of peak expiratory flow in early di-
agnosis of chronic obstructive pulmonary disease (COPD). In view of high cost and unavailability of spirometry
and the ever-increasing prevalence of COPD as a result of cigarette smoking, this study can do much to lighten
the economic burden in national health system. Materials and Methods: We examined 250 patients taking
spirometry test in Shohadaye Tajrish Hospital during 2008, chosen by simple random sampling method. COPD
was defined as FEV/FVC<70% according to existing resources. PEF values smaller than 80% were considered
as abnormal based on ATS criteria. We assessed PEF sensitivity in comparison with FEV1/FVC. Results: COPD
prevalence among spirometry tests was 21.2%. Out of the patients, 76.27% were male and 92.9% were older than
40. PEF sensitivity was 74% and its specificity was 97.5%. Discussion: The higher COPD prevalence among men
may be explained by higher cigarette smoking rate among men than in women in our country. Moreover, COPD
occurrence risk increases with age. Conclusion: The positive predictive value of PEF compared with EFV1/FVC
reveals that this test is an appropriate diagnostic tool which can diagnose COPD earlier than EFV1/FVC.
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1. Introduction
With great advances in different scientific areas, medical so-
ciety is increasingly paying attention to the quality of life (1).
COPD is a major debilitating disease defined as irreparable
obstruction of air flow (2). COPD prevalence is estimated to
be 10.1% for stage u and above (11.8% in men and 8.5% in
women) and varies from one country to another. Studies re-
port the prevalence to be 17% in USA, 9.9% in UK, 10.1% in
Denmark, 8% in Sweden, 7.6% in India and 14.3% in Spain
(3). The prevalence also increases with age (2). This number
will rise if spirometry is used rather than relying on clinical
examination. If we accept GOLD criteria in spirometry in-
terpretation, COPD prevalence in UK reaches to 18% in gen-
eral and 29% in people above 46 (4). We should also bear in
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mind that only 18.6% of these people are identified (5). The
ever-increasing prevalence of this disease makes it impera-
tive to conduct a study on early diagnosis and treatment of
COPD(6).
COPD causes activity limitation for 14 million days per year
and causes disability for 50 million days per year. It is the only
cause of mortality to be on the rise, with 22% increase over
the recent two decades (7, 8). The number of patients with
COPD has doubled during the past 25 years and the 10-year
post-diagnosis fatality rate is over 50% (9, 10). The most im-
portant risk factor associated with COPD is cigarette smok-
ing, with nearly half of middle-aged male smokers having ab-
normal spirometry. Fatality rate of smokers is 10 times that of
non-smokers (5, 11).
Spirometry is the best COPD diagnostic tool, but it is expen-
sive, unavailable and hard-to-use. Such disadvantages have
discouraged the early treatment of the disease and made it
essential to find a practical, easy-to-use, and cheap diagnos-
tic tool (11).
Peak flow meter was first introduced in 1959 as a portable
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tool for examining lung function in emergency conditions. It
is a simple and repeatable device which shows the amount of
air flow obstruction. PEF is the highest air value in a deep ex-
halation. Precise measurement requires an accurate inhala-
tion followed by a deep exhalation (12, 13).
This value can be measured by spirometer or peak flow me-
ter. PEF is used to assess the strength of air ways, person’s ef-
fort, neuromuscular health and elasticity. Since the reliability
of data produced by this device is highly associated with pa-
tient’s effort, the best solution for obtaining a precise number
is to inform the patient about the proper technique (13, 14).
A major application of peak flow meter is the management
of asthma. Where spirometry is not diagnostic for a patient
with asthma symptoms, this device is the best tool for diag-
nosing COPD and distinguishing it from asthma(13, 15) .
PEF is minimal in morning and maximal in evening. 20%
difference between morning and evening values is diagnos-
tic for asthma. A major application of PEF is the diagnosis
and treatment of exacerbation asthma. 50≤PEF≤80% indi-
cates risk and tells the patient to see a doctor and increase
the number of bronchodilators (14, 16). 50 %< PEF indicates
exacerbation. A random study on asthmatic patients reports
16% increase in FEV1 after the lapse of 18 months (17, 18).
While some researchers have analyzed the role of PEF in early
diagnosis and treatment of COPD, there is no consensus on
the application of PEF. The materials available in guideline
continue to emphasize the use of FEV1 as a diagnostic tool
(19, 20). Some research has suggested that COPD diagnosis
with mere clinical examination is infeasible and final diag-
nosis requires further examinations such as PFT. Moreover,
while spirometry produces precise data, general practition-
ers are more familiar with PEF and find it difficult to use
spirometry (13).
On the other hand, since PFT drop in people with COPD oc-
curs slowly, annual or biennial execution does not produce
sufficient information. So, it is necessary to use another tool
for assessing COPD acute attack (21).
It could be said, therefore, that spirometry is not appropri-
ate for patient screening as it is hard-to-access and time-
consuming. Some research has suggested that social protec-
tion entails the supervision of all smokers in the society. As
this is impossible, we have to focus on heavy smokers and old
people. Obviously, PEF is a suitable tool for assessing this big
group of the society thanks to its availability, low price and
reliability.
Given the above facts, it is essential to conduct a study on
PEF sensitivity in comparison with FEV1 in the diagnosis and
treatment of COPD.
2. Materials and Methods
This is an observational and analytical study performed
during a limited period. Samples were selected by sim-
ple random sampling method from among spirometry tests
performed for one year (April 2008 through March 2009)
in Shohada Tajrish Hospital. We examined 250 patients
based on n=z2(1-a)pq/d2 ,with a-5% and prevalence of 18%
in spirometry (FEV1/FVC<70%). All patients took similar
spirometry tests and unreliable samples with non-standard
flow-volume curve were excluded from study.
Age and gender distribution of samples was determined and
then the data was statistically analyzed. Based on the exist-
ing resources, standard definition was set on FEV1/FVC<70%
and the patients were divided into three groups of light, aver-
age and heavy according to severity of disease. PEF<80% was
set as a sign of obstruction. We assessed the amount of sen-
sitivity and specificity in comparison with FEV1/FVC in the
diagnosis of obstruction.
3. Results
We examined 250 randomly selected spirometry tests per-
formed during 2008 in Shohada Tajrish Hospital and ob-
tained a prevalence of 21.2%. 67.5% of the candidates were
male, 41.8% were below the age of 40, 33.8% were between
40 and 60, 24.3% were above 60. Out of the patients with ob-
structive disease, 76.27% were male and 92.9% were above
the age of 45. (Figure1)
Obstructive disease was confirmed in 48.9% of patients who
were older than 65. This number was 17.5% for the age of 65
and below. (Figure2)
Out of the patients with obstructive disease, 8% had mild ob-
struction, 35.4% had moderate obstruction, and 56.5% had
severe obstruction.
We compared PEF with FEV1/FVC in the diagnosis of COPD
based on ATS criteria and ROC and obtained the following
results. Since other resources have confirmed FEV1/FVC as
COPD diagnosis standard, we calculated PEF sensitivity in
the diagnosis of COPD based on these resources. (Table1)
On the other hand, since FEV1 / FVC is accepted as the airway
obstruction detection standard in other sources, we calcu-
lated the PEF sensitivity for COPD diagnosis based on these
sources. (Table 2)
4. Discussion
Do we know any test which can show air flow obstruction
in shortest time? The debate on the use of spirometry for
the above purpose remains open and physicians often decide
based on their own experiences.
In 1988 Kelly Gibson describe in their article that Spirome-
try has more sensitivity than PEF in COPD also they showed
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strength correlation between FEV1 and PEF (22).
However other article shows strength correlation between
FEV1 and PEF (r=0.95) but none of them showed that FEV1
is superior to PEF. It seems that in same sensitivity PEF is
superior to FEV1 because of cheapness and feasibility (23).
in a cross-sectional study by national health and nutritional
estimated survey (NHANES) in COPD patients according to
FEV1/FVC<70% and FEV1<80% and PEF<80 % as standard
criteria PEF sensitivity for overall COPD case was 90% and for
moderate to severe case has 100% sensitivity and 80% speci-
ficity (24). Dr. White article despite superiority of FEV1 men-
tion that PEF validity and even reproducibility is more than
FEV1(25).
COPD despite other chronic disease lick, DM, HTN, IHD has
two phases stable and unstable or exacerbation, treatment
of exacerbation has much more benefit and PEF can find the
case of COPD exacerbation so is a good tool for diagnosis and
treatment in this stage (26, 27).
COPD prevalence percentage obtained by this study is in line
with previous statistics. The prevalence is higher in men than
in women, which may be explained by higher cigarette smok-
ing rate among men in our country. If we define obstruction
as FEV1/FVC<70% according to reputable resources, the re-
sults reveal a sensitivity of 74% and positive predictive value
of 98%. PEF reduction before drop in FEV1/FVC is indicative
of obstruction. In other words, PEF drops at the time of re-
duction in the above ratio, but the contrary is very unlikely
(false negative smaller than 2%). Moreover, the negative pre-
dictive value indicates that if PEF does not drop, air flow ob-
struction can be rejected with high confidence. This is also
supported by the validity of 81.2%.
5. Conclusion
The results obtained by this study suggest that PEF reduction
may be an early indication of air flow obstruction. Although
different resources continue to emphasize that FEV1/FVC ra-
tio is diagnostic of COPD, peak flow meter is a cheap and
easy-to-access tool with high sensitivity which can play an
important role in COPD diagnosis. Furthermore, given the
high negative predictive value obtained for this test, it can
dispense with complicated and expensive diagnostic tests
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Positive predictive value: 93.8%
Negative predictive value: 75.8%






Positive predictive value: 98%
Negative predictive value: 62.5%
Validity: 81.2%
Figure 1: Distribution of obstruction percentage according to patient sex.
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Figure 2: Distribution of obstruction percentage according to patient age.
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